% | $
Quotes you view appear here for quick access.

Qiagen NV Message Board

accurateinformation 6 posts  |  Last Activity: Jul 7, 2016 6:35 PM Member since: Oct 16, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Illumina, Sequenom Under Investigation for Anticompetitive Conduct
    Published Wednesday, July 06, 2016

    At a Case Management Conference on Friday 1 July, the English Court ordered that it would consider Premaitha’s competition law defence after the patent hearings scheduled for July 2017, when it would have more certainty on the validity of the technical claims made, and an ongoing investigation by the European Commission ( into potentially anticompetitive conduct by Illumina and Sequenom in the NIPT market. Illumina’s attempts to have the defence dismissed were refused.
    The Court also ordered Illumina to provide an unredacted copy of a Pooled Patents Agreement to the Company’s legal advisers, which Illumina had previously refused. The PPA was entered into by Illumina and Sequenom in late 2014 and is the basis for the patent litigation claims made by the Claimants against the Company in the UK and against its customers in Poland and Switzerland, along with similar litigation against other competitors that do not use Illumina sequencing platforms for their NIPT solutions. In its reasoning, the Court stated that disclosure of the PPA will very probably “shed some light on the competition arguments that are being raised”.

    Sentiment: Strong Sell

  • Reply to

    Dirk bought today

    by btommasino Jun 8, 2016 6:41 PM
    accurateinformation accurateinformation Jun 8, 2016 9:17 PM Flag


    The 40,000 shares he bought brings the value of his total shares owned to under $190,00....TOTAL even after all the years he has been with the company!

    That is all he owns! That show he has no faith in the company that he runs

    Sentiment: Strong Sell

  • accurateinformation accurateinformation May 20, 2016 4:37 PM Flag

    Lie much? Why, YES YOU DO!

    Yahoo shows I have posts this year alone, over 80 since the beginning of last year, and hundreds of others over the years.

    So why are you lying?

    Sentiment: Sell

  • accurateinformation accurateinformation May 20, 2016 12:17 PM Flag

    Because this was approved by the FDA as a prescription only test, if EXAS knowingly fills a prescription for off-label use, a use not included in their FDA approved labeling , such as a replacement for routine colonoscopy, they are definitely in violation of the FDA regulations.

    Sentiment: Sell

  • accurateinformation accurateinformation May 20, 2016 11:05 AM Flag

    I am simply pointing out that CG IS NOT intended as a replacement for colonoscopy. It is intended simply as an alternative to FIT.

    So all of the clueless posters here that keep touting CG as a replacement for colonoscopy are scammers.

    And if EXAS itself is promoting CG as a replacement for routine colonoscopy they are violating the FDA regulations and have a mislabeled product.

    Sentiment: Sell

  • "Today’s approval of the Cologuard does not change current practice guidelines for colorectal cancer screening. Stool DNA testing (also called “fecal DNA testing”) is not currently recommended as a method to screen for colorectal cancer by the United States Preventive Services Task Force (USPSTF). Among other guidelines, the USPSTF recommends adults age 50 to 75, at average risk for colon cancer, be screened using fecal occult blood testing, sigmoidoscopy, or colonoscopy."

    Sentiment: Strong Sell

27.30-0.11(-0.40%)Sep 28 4:00 PMEDT